Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05084963Phase 2Completed

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

Role: lead

NCT05921591Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

Role: lead

NCT05098522Phase 2Completed

Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis

Role: lead

NCT04748536Phase 1Completed

Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

Role: lead

All 4 trials loaded